AB Science has announced that a program for the clinical development of masitinib in sickle-cell anemia has been selected as one of the 19 winning projects in the sixth call for projects for "hospital-university health research" under the "Programme d'investissements d'avenir".

Within this framework, the SICKMAST project will receive funding of 9.2 million euros, notably for a Phase II clinical trial to evaluate the efficacy of masitinib in this widespread genetic disease. The AP-HP will be the sponsor of this trial.

AB Science will be involved mainly through the supply of masitinib and in monitoring the product's pharmacovigilance data. It remains free to carry out the phase III trial that will follow on from phase II should it be successful.

Copyright (c) 2023 CercleFinance.com. All rights reserved.